Analysis of TGF-β and TGF-β-RII in thyroid neoplasms from the United States, Japan, and China

Yoshiaki Imamura, Long Jin, Joseph Peter Grande, Chin Yang Li, T. R. Zheng, Lori A. Erickson, Ricardo V. Lloyd

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Transforming growth factor-β (TGF-β) has an inhibitory effect on cell proliferation in various cells and tumors, so loss of TGF-β-receptor (TGF- β-R) may lead to increase proliferative activity in these tumors. We compared the expression of TGF-β and TGF-β-RII in a group of thyroid neoplasms from the United States, Japan, and China to determine if there were differences in the expression of this growth factor or its receptors in various tumor types from different countries. A total 108 neoplastic thyroids from the United States, 42 from Japan, and 46 from China were analyzed for TGF-β1, TGF-β3, and TGF-β-RII by in situ hybridization with riboprobes. TGF-β-RII expression was also examined by immunohistochemistry. TGF-β1 mRNA was expressed in all neoplastic thyroids from all three countries except for one anaplastic carcinoma (ACA). TGF-β3 expression was lowest in follicular carcinomas (FCA) from all three countries (30/42; 71%). TGF-β-RII was much lower in FCA from Japan (1/2; 50%) and China (6/11; 55%) compared to cases from the United States (26/29; 90%). TGF-β-RII expression in papillary carcinoma (PCA) was also lower in carcinomas from Japan (21/28; 75%) and China (23/30; 77%) compared to the United States (24/25; 96%). Most ACA from the United States (25/30; 83%) and from China (3/3; 100%) were positive for TGF-β-RII. Immunohistochemical analysis for TGF-β-RII protein expression showed the highest levels in follicular adenomas (FA) (38/38; 100%) with decreased immunoreactivity in FCA (36/42; 86%), PCA (66/83; 80%), and ACA (14/33; 42%). These findings suggest that loss of TGF-β-RII may be important in thyroid tumor progression and that environmental/geographic factors may play a role in the variable expression of TGF-β-RII in thyroid malignancy.

Original languageEnglish (US)
Pages (from-to)209-216
Number of pages8
JournalEndocrine Pathology
Volume9
Issue number3
StatePublished - 1998

Fingerprint

Transforming Growth Factors
Thyroid Neoplasms
China
Japan
Carcinoma
Thyroid Gland
Papillary Carcinoma
Neoplasms
Geography
Growth Factor Receptors
Adenoma
In Situ Hybridization

Keywords

  • In situ hybridization
  • Riboprobe
  • TGF-β
  • TGF-β-RII
  • Thyroid

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pathology and Forensic Medicine

Cite this

Imamura, Y., Jin, L., Grande, J. P., Li, C. Y., Zheng, T. R., Erickson, L. A., & Lloyd, R. V. (1998). Analysis of TGF-β and TGF-β-RII in thyroid neoplasms from the United States, Japan, and China. Endocrine Pathology, 9(3), 209-216.

Analysis of TGF-β and TGF-β-RII in thyroid neoplasms from the United States, Japan, and China. / Imamura, Yoshiaki; Jin, Long; Grande, Joseph Peter; Li, Chin Yang; Zheng, T. R.; Erickson, Lori A.; Lloyd, Ricardo V.

In: Endocrine Pathology, Vol. 9, No. 3, 1998, p. 209-216.

Research output: Contribution to journalArticle

Imamura, Y, Jin, L, Grande, JP, Li, CY, Zheng, TR, Erickson, LA & Lloyd, RV 1998, 'Analysis of TGF-β and TGF-β-RII in thyroid neoplasms from the United States, Japan, and China', Endocrine Pathology, vol. 9, no. 3, pp. 209-216.
Imamura, Yoshiaki ; Jin, Long ; Grande, Joseph Peter ; Li, Chin Yang ; Zheng, T. R. ; Erickson, Lori A. ; Lloyd, Ricardo V. / Analysis of TGF-β and TGF-β-RII in thyroid neoplasms from the United States, Japan, and China. In: Endocrine Pathology. 1998 ; Vol. 9, No. 3. pp. 209-216.
@article{63a1fe39879c4e7eb97104a53fa61a6d,
title = "Analysis of TGF-β and TGF-β-RII in thyroid neoplasms from the United States, Japan, and China",
abstract = "Transforming growth factor-β (TGF-β) has an inhibitory effect on cell proliferation in various cells and tumors, so loss of TGF-β-receptor (TGF- β-R) may lead to increase proliferative activity in these tumors. We compared the expression of TGF-β and TGF-β-RII in a group of thyroid neoplasms from the United States, Japan, and China to determine if there were differences in the expression of this growth factor or its receptors in various tumor types from different countries. A total 108 neoplastic thyroids from the United States, 42 from Japan, and 46 from China were analyzed for TGF-β1, TGF-β3, and TGF-β-RII by in situ hybridization with riboprobes. TGF-β-RII expression was also examined by immunohistochemistry. TGF-β1 mRNA was expressed in all neoplastic thyroids from all three countries except for one anaplastic carcinoma (ACA). TGF-β3 expression was lowest in follicular carcinomas (FCA) from all three countries (30/42; 71{\%}). TGF-β-RII was much lower in FCA from Japan (1/2; 50{\%}) and China (6/11; 55{\%}) compared to cases from the United States (26/29; 90{\%}). TGF-β-RII expression in papillary carcinoma (PCA) was also lower in carcinomas from Japan (21/28; 75{\%}) and China (23/30; 77{\%}) compared to the United States (24/25; 96{\%}). Most ACA from the United States (25/30; 83{\%}) and from China (3/3; 100{\%}) were positive for TGF-β-RII. Immunohistochemical analysis for TGF-β-RII protein expression showed the highest levels in follicular adenomas (FA) (38/38; 100{\%}) with decreased immunoreactivity in FCA (36/42; 86{\%}), PCA (66/83; 80{\%}), and ACA (14/33; 42{\%}). These findings suggest that loss of TGF-β-RII may be important in thyroid tumor progression and that environmental/geographic factors may play a role in the variable expression of TGF-β-RII in thyroid malignancy.",
keywords = "In situ hybridization, Riboprobe, TGF-β, TGF-β-RII, Thyroid",
author = "Yoshiaki Imamura and Long Jin and Grande, {Joseph Peter} and Li, {Chin Yang} and Zheng, {T. R.} and Erickson, {Lori A.} and Lloyd, {Ricardo V.}",
year = "1998",
language = "English (US)",
volume = "9",
pages = "209--216",
journal = "Endocrine Pathology",
issn = "1046-3976",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Analysis of TGF-β and TGF-β-RII in thyroid neoplasms from the United States, Japan, and China

AU - Imamura, Yoshiaki

AU - Jin, Long

AU - Grande, Joseph Peter

AU - Li, Chin Yang

AU - Zheng, T. R.

AU - Erickson, Lori A.

AU - Lloyd, Ricardo V.

PY - 1998

Y1 - 1998

N2 - Transforming growth factor-β (TGF-β) has an inhibitory effect on cell proliferation in various cells and tumors, so loss of TGF-β-receptor (TGF- β-R) may lead to increase proliferative activity in these tumors. We compared the expression of TGF-β and TGF-β-RII in a group of thyroid neoplasms from the United States, Japan, and China to determine if there were differences in the expression of this growth factor or its receptors in various tumor types from different countries. A total 108 neoplastic thyroids from the United States, 42 from Japan, and 46 from China were analyzed for TGF-β1, TGF-β3, and TGF-β-RII by in situ hybridization with riboprobes. TGF-β-RII expression was also examined by immunohistochemistry. TGF-β1 mRNA was expressed in all neoplastic thyroids from all three countries except for one anaplastic carcinoma (ACA). TGF-β3 expression was lowest in follicular carcinomas (FCA) from all three countries (30/42; 71%). TGF-β-RII was much lower in FCA from Japan (1/2; 50%) and China (6/11; 55%) compared to cases from the United States (26/29; 90%). TGF-β-RII expression in papillary carcinoma (PCA) was also lower in carcinomas from Japan (21/28; 75%) and China (23/30; 77%) compared to the United States (24/25; 96%). Most ACA from the United States (25/30; 83%) and from China (3/3; 100%) were positive for TGF-β-RII. Immunohistochemical analysis for TGF-β-RII protein expression showed the highest levels in follicular adenomas (FA) (38/38; 100%) with decreased immunoreactivity in FCA (36/42; 86%), PCA (66/83; 80%), and ACA (14/33; 42%). These findings suggest that loss of TGF-β-RII may be important in thyroid tumor progression and that environmental/geographic factors may play a role in the variable expression of TGF-β-RII in thyroid malignancy.

AB - Transforming growth factor-β (TGF-β) has an inhibitory effect on cell proliferation in various cells and tumors, so loss of TGF-β-receptor (TGF- β-R) may lead to increase proliferative activity in these tumors. We compared the expression of TGF-β and TGF-β-RII in a group of thyroid neoplasms from the United States, Japan, and China to determine if there were differences in the expression of this growth factor or its receptors in various tumor types from different countries. A total 108 neoplastic thyroids from the United States, 42 from Japan, and 46 from China were analyzed for TGF-β1, TGF-β3, and TGF-β-RII by in situ hybridization with riboprobes. TGF-β-RII expression was also examined by immunohistochemistry. TGF-β1 mRNA was expressed in all neoplastic thyroids from all three countries except for one anaplastic carcinoma (ACA). TGF-β3 expression was lowest in follicular carcinomas (FCA) from all three countries (30/42; 71%). TGF-β-RII was much lower in FCA from Japan (1/2; 50%) and China (6/11; 55%) compared to cases from the United States (26/29; 90%). TGF-β-RII expression in papillary carcinoma (PCA) was also lower in carcinomas from Japan (21/28; 75%) and China (23/30; 77%) compared to the United States (24/25; 96%). Most ACA from the United States (25/30; 83%) and from China (3/3; 100%) were positive for TGF-β-RII. Immunohistochemical analysis for TGF-β-RII protein expression showed the highest levels in follicular adenomas (FA) (38/38; 100%) with decreased immunoreactivity in FCA (36/42; 86%), PCA (66/83; 80%), and ACA (14/33; 42%). These findings suggest that loss of TGF-β-RII may be important in thyroid tumor progression and that environmental/geographic factors may play a role in the variable expression of TGF-β-RII in thyroid malignancy.

KW - In situ hybridization

KW - Riboprobe

KW - TGF-β

KW - TGF-β-RII

KW - Thyroid

UR - http://www.scopus.com/inward/record.url?scp=0031763010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031763010&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 209

EP - 216

JO - Endocrine Pathology

JF - Endocrine Pathology

SN - 1046-3976

IS - 3

ER -